Clinical Outcomes of Japanese Encephalitis after Combination Treatment of Immunoglobulin, Ribavirin, and Interferon-α2b
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Japanese encephalitis (JE) is caused by the JE virus of the Flaviviridae family and is spread by mosquito bites, and no specific antiviral treatment for it exists. Here we describe the clinical presentations, laboratory findings, clinical outcomes, and adverse events after combination treatment of immunoglobulin, ribavirin, and interferon-α2b administered to patients with JE. Methods Data were collected and reviewed from a prospective cohort of encephalitis patients admitted to Seoul National University Hospital between August 1, 2010 and October 31, 2019. We reviewed the medical records of the patients diagnosed with JE and treated either with supportive care only or with combination treatment of intravenous immunoglobulin, oral ribavirin, and subcutaneous interferon-α2b. Results Eleven patients were diagnosed with laboratory-confirmed JE based on the diagnosis criteria of JE. The median age was 61 years, and five patients were male. Eight patients were treated with the combination therapy, while three patients received supportive management only. Four of the eight patients (50%) treated with the combination therapy showed partial recovery, while one patient (12.5%) showed complete recovery. Two patients experienced hemolytic anemia related to ribavirin and febrile reaction to immunoglobulin, respectively. Among the three patients who received supportive management only, one (33.3%) showed partial recovery and the other two (67.7%) did not show improvement. Conclusions Combination treatment of immunoglobulin, ribavirin, and interferon-α2b was found to be tolerable in JE in this study. Further studies of appropriate designs and involving larger numbers of patients are warranted to explore the efficacy of this combination therapy.
Abstract
Background and Purpose Japanese encephalitis (JE) is caused by the JE virus of the Flaviviridae family and is spread by mosquito bites, and no specific antiviral treatment for it exists. Here we describe the clinical presentations, laboratory findings, clinical outcomes, and adverse events after combination treatment of immunoglobulin, ribavirin, and interferon-α2b administered to patients with JE. Methods Data were collected and reviewed from a prospective cohort of encephalitis patients admitted to Seoul National University Hospital between August 1, 2010 and October 31, 2019. We reviewed the medical records of the patients diagnosed with JE and treated either with supportive care only or with combination treatment of intravenous immunoglobulin, oral ribavirin, and subcutaneous interferon-α2b. Results Eleven patients were diagnosed with laboratory-confirmed JE based on the diagnosis criteria of JE. The median age was 61 years, and five patients were male. Eight patients were treated with the combination therapy, while three patients received supportive management only. Four of the eight patients (50%) treated with the combination therapy showed partial recovery, while one patient (12.5%) showed complete recovery. Two patients experienced hemolytic anemia related to ribavirin and febrile reaction to immunoglobulin, respectively. Among the three patients who received supportive management only, one (33.3%) showed partial recovery and the other two (67.7%) did not show improvement. Conclusions Combination treatment of immunoglobulin, ribavirin, and interferon-α2b was found to be tolerable in JE in this study. Further studies of appropriate designs and involving larger numbers of patients are warranted to explore the efficacy of this combination therapy.
참고문헌 (18)
- Sikka V, "The emergence of Zika virus as a global health security threat : a review and a consensus statement of the INDUSEM Joint Working Group(JWG)", J Glob Infect Dis, 8, pp.3~15 (2016)
- Tsai TF, "New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO", CVI meeting, Bangkok, Thailand, 13-15October 1998, 2000, pp.18(Suppl 2), 1~25
- Solomon T, "Interferon alfa-2a in Japanese encephalitis : a randomised double-blind placebo-controlled trial", Lancet, 361, pp.821~826 (2003)
- Hoke CH Jr, "Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus", J Infect Dis, 165, pp.631~637 (1992)
- Sunwoo JS, "Reemergence of Japanese encephalitis in South Korea, 2010-2015", Emerg Infect Dis, 22, pp.1841~1843 (2016)
- Anderson JF, "Efficacy of interferon α-2b and ribavirin against West Nile virus in vitro", Emerg Infect Dis, 8, pp.107~108 (2002)
- Ben-Nathan D, "Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice", J Infect Dis, 188, pp.5~12 (2003)
- Falzarano D, "Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques", Nat Med, 19, pp.1313~1317 (2013)
- Omrani AS, "Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection : a retrospective cohort study", Lancet Infect Dis, 14, pp.1090~1095 (2014)
- Common terminology criteria for adverse events (CTCAE), "National Cancer Institute (U.S.)", U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute, ~ (2009)
- Růžek D, "May early intervention with high dose intravenous immunoglobulin pose a potentially successful treatment for severe cases of tick-borne encephalitis?", BMC Infect Dis, 13, pp.306~ (2013)
- Sullivan KM, "Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation", N Engl J Med, 323, pp.705~712 (1990)
- Walid MS, "Successful treatment with intravenous immunoglobulin of acute flaccid paralysis caused by West Nile virus", Perm J, 13, pp.43~46 (2009)
- Shimoni Z, "Treatment of West Nile virus encephalitis with intravenous immunoglobulin", Emerg Infect Dis, 7, pp.759~ (2001)
- Feld JJ, "Mechanism of action of interferon and ribavirin in treatment of hepatitis C", Nature, 436, pp.967~972 (2005)
- Jiang D, "Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus", J Virol, 82, pp.1665~1678 (2008)
- Thomas E, "Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models", Hepatology, 53, pp.32~41 (2011)
- Manns MP, "Treating viral hepatitis C : efficacy, side effects, and complications", Gut, 55, pp.1350~1359 (2006)